Evidence mapPaperPMID 37282805Full record

ArticleAdvanced healthcare materials2023

Transformative Materials for Interfacial Drug Delivery.

Prachi Desai, Anshuman Dasgupta, Alexandros Marios Sofias, Quim Peña, Robert Göstl, Ioana Slabu, Ulrich Schwaneberg, Thomas Stiehl, Wolfgang Wagner, Stefan Jockenhövel and 7 more

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Transformative Materials for Interfacial Drug Delivery.Advanced healthcare materials · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Prachi DesaiInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.ORCID 0000-0003-2471-0739
Anshuman DasguptaInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.
Alexandros Marios SofiasInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.ORCID 0000-0002-7475-2526
Quim PeñaInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.ORCID 0000-0001-6477-8127
Robert GöstlDWI - Leibniz Institute for Interactive Materials, 52074, Aachen, Germany.ORCID 0000-0002-7483-6236
Ioana SlabuInstitute of Applied Medical Engineering, Helmholtz Institute, Medical Faculty, RWTH Aachen University, 52074, Aachen, Germany.ORCID 0000-0002-8945-4310
Ulrich SchwanebergInstitute of Biotechnology, RWTH Aachen University, 52074, Aachen, Germany.ORCID 0000-0003-4026-701X
Thomas StiehlCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIOABCD), 52074, Aachen, Germany.ORCID 0000-0001-9686-9197
Wolfgang WagnerCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIOABCD), 52074, Aachen, Germany.ORCID 0000-0002-1971-3217
Stefan JockenhövelDepartment of Biohybrid & Medical Textiles (BioTex), AME - Institute of Applied Medical Engineering, Helmholtz Institute Aachen, RWTH Aachen University, 52074, Aachen, Germany.ORCID 0000-0003-0584-9444
Julia StinglInstitute of Clinical Pharmacology, University Hospital RWTH Aachen, 52074, Aachen, Germany.ORCID 0000-0002-1566-8156
Rafael KramannDivision of Nephrology and Clinical Immunology, RWTH Aachen University, 52074, Aachen, Germany.ORCID 0000-0003-4048-6351
Christian TrautweinCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIOABCD), 52074, Aachen, Germany.
Tim H BrümmendorfCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIOABCD), 52074, Aachen, Germany.
Fabian KiesslingInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.ORCID 0000-0002-7341-0399
Andreas HerrmannDWI - Leibniz Institute for Interactive Materials, 52074, Aachen, Germany.ORCID 0000-0002-8886-0894
Twan LammersInstitute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.ORCID 0000-0002-1090-6805

Funding

European Research Council 864121
6 · The paper itself

Abstract

Drug delivery systems (DDS) are designed to temporally and spatially control drug availability and activity. They assist in improving the balance between on-target therapeutic efficacy and off-target toxic side effects. DDS aid in overcoming biological barriers encountered by drug molecules upon applying them via various routes of administration. They are furthermore increasingly explored for modulating the interface between implanted (bio)medical materials and host tissue. Herein, an overview of the biological barriers and host-material interfaces encountered by DDS upon oral, intravenous, and local administration is provided, and material engineering advances at different time and space scales to exemplify how current and future DDS can contribute to improved disease treatment are highlighted.

Indexed as

Drug Delivery SystemsPharmaceutical PreparationsPharmaceutical Preparationsbiomaterialsbiomedical engineeringdrug deliverydrug targetingnanomedicines

Identifiers

PMID37282805
PMCPMC11468550

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.